NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics. 
 
The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.
 
Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.
 
Financial terms of the agreement were not released.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.